Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 1/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | LPL | P06858 | 1/20 | 0.31 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8630769 | 0.84 | HCAR3 (0.38) | HCAR3HCAR2BACE1KCNH2KIF11 | |
| SCHEMBL9741477 | 0.73 | CHRM1 (0.37) | HCAR3HCAR2BACE1KCNH2KIF11 | |
| SCHEMBL873359 | 0.71 | CHRNB2 (0.41) | CHRM1SLC6A2 | |
| SCHEMBL3995603 | 0.68 | TAAR1 (0.43) | SLC6A2SLC6A4 | |
| SCHEMBL994874 | 0.68 | — | — | |
| SCHEMBL9557318 | 0.65 | KCNA3 (0.36) | HCAR3HCAR2BACE1KCNH2KIF11 | |
| SCHEMBL9632887 | 0.64 | HCAR3 (0.38) | HCAR3HCAR2KIF11CHRM1LPL | |
| SCHEMBL3996025 | 0.64 | TRPA1 (0.32) | KCNH2 | |
| SCHEMBL13808489 | 0.64 | KCNH2 (0.31) | KCNH2 | |
| SCHEMBL20217389 | 0.64 | KCNA3 (0.35) | HCAR3HCAR2KIF11CHRM1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8344136-B2 | Process for the preparation of brinzolamide | PHF S.A. (CH) | 2013-01-01 | — | — | US | disclosed |
| US-8344136-B2 | Process for the preparation of brinzolamide | PHF S.A. (CH) | 2013-01-01 | — | — | US | disclosed |
| US-20110118461-A1 | PROCESS FOR THE PREPARATION OF BRINZOLAMIDE | F.I.S. - FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2011-05-19 | — | — | US | disclosed |
| US-20110118461-A1 | PROCESS FOR THE PREPARATION OF BRINZOLAMIDE | F.I.S. - FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2011-05-19 | — | — | US | disclosed |
| US-20100317655-A1 | SULFONAMIDE INHIBITORS OF CARBONIC ANHYDRASE | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-12-16 | — | — | US | disclosed |
| US-20100317655-A1 | SULFONAMIDE INHIBITORS OF CARBONIC ANHYDRASE | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-12-16 | — | — | US | disclosed |
| US-20100317655-A1 | SULFONAMIDE INHIBITORS OF CARBONIC ANHYDRASE | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-12-16 | — | — | US | disclosed |
| US-20100009977-A1 | Process for the preparation of (R)-(+)-4-(Ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide-1,1-dioxide. | USV LTD. (IN) | 2010-01-14 | — | — | US | disclosed |
| US-20100009977-A1 | Process for the preparation of (R)-(+)-4-(Ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide-1,1-dioxide. | USV LTD. (IN) | 2010-01-14 | — | — | US | disclosed |
| US-20100009977-A1 | Process for the preparation of (R)-(+)-4-(Ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide-1,1-dioxide. | USV LTD. (IN) | 2010-01-14 | — | — | US | disclosed |
| US-5679670-A | CONTROLLING INTRAOCULAR PRESSURE | ALCON LABORATORIES, INC. (US) | 1997-10-21 | — | — | US | disclosed |
| WO-1996022099-A1 | OPHTHALMIC COMPOSITIONS FOR TREATING GLAUCOMA | ALCON LABORATORIES, INC. (US) | 1996-07-25 | — | — | WO | disclosed |
| US-5538966-A | ENZYME INHIBITORS FOR TREATMENT OF GLAUCOMA | ALCON LABORATORIES, INC. (US) | 1996-07-23 | — | — | US | disclosed |
| WO-1995019981-A1 | THIENOTHIAZINE SULFONAMIDE DERIVATIVES PROCESS AND INTERMEDIATES FOR THEIR PREPARATION AND THEIR USE AS CARBONIC ANHYDRASE INHIBITORS | ALCON LABORATORIES, INC. (US) | 1995-07-27 | — | — | WO | disclosed |
| US-5378703-A | FOR CONTROLLING INTRAOCULAR PRESSURE | ALCON LABORATORIES, INC. (US) | 1995-01-03 | — | — | US | disclosed |
| US-5240923-A | Treating glaucoma | ALCON LABORATORIES, INC. (US) | 1993-08-31 | — | — | US | disclosed |
| EP-0527801-A4 | THIOPHENE SULFONAMIDES USEFUL AS CARBONIC ANYDRASE INHIBITORS | — | 1993-03-10 | — | — | EP | disclosed |
| EP-0527801-A1 | THIOPHENE SULFONAMIDES USEFUL AS CARBONIC ANYDRASE INHIBITORS | ALCON LABORATORIES, INC. (US) | 1993-02-24 | — | — | EP | disclosed |
| US-5153192-A | For controlling intraocular pressure | ALCON LABORATORIES, INC. (US) | 1992-10-06 | — | — | US | disclosed |
| WO-1991015486-A1 | THIOPHENE SULFONAMIDES USEFUL AS CARBONIC ANYDRASE INHIBITORS | ALCON LABORATORIES, INC. (US) | 1991-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009977-A1 | Process for the preparation of (R)-(+)-4-(Ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide-1,1-dioxide. | SULT1E1, SULT1A1, SULT2A1 | HCAR3 3022/4885HCAR2 1836/4885BACE1 1571/4885 |
| US-20100317655-A1 | SULFONAMIDE INHIBITORS OF CARBONIC ANHYDRASE | CA2, CA9, CA1 | HCAR3 534/4885HCAR2 142/4885BACE1 1752/4885 |
| US-20110118461-A1 | PROCESS FOR THE PREPARATION OF BRINZOLAMIDE | CYP3A4, CYP4B1, SULT1E1 | HCAR3 2879/4885HCAR2 1727/4885BACE1 1535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.